Sign in
Taking peopleNo phase

Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
China5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
560 people, planned
Started
29 Jan 2026
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ALA-PDT
  • LEEP surgery
Record updated
14 October 2026

Who can take part

Age
25 years to 65 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Female, 25-60 years, understands study procedures and consents to participate
  • Colposcopy-guided cervical biopsy within 3 months showing HSIL/CIN2
  • Provides written informed consent

Who cannot take part

  • Use of interferon or antiviral therapy within 3 months
  • Cytology showing ASC-H, HSIL, AGC, or AIS; or evidence of malignant cells on cytology/histology, or suspicion of malignancy or invasive cancer
  • Colposcopy findings suggestive of invasive cancer or lesion extension to the vaginal wall
  • Severe pelvic, cervical, or other gynecological inflammatory conditions identified clinically
  • Undiagnosed vaginal bleeding
  • Active allergic disease, porphyria, or history of allergy to the study drug or structurally similar agents
  • Severe cardiovascular, neurological, psychiatric, endocrine, hepatic, or hematologic disorders; known immunodeficiency; long-term glucocorticoid or immunosuppressant use; active autoimmune disease; or other malignancies
  • History of hysterectomy, cervical cancer treatment, or cervical excision/ablation within 6 months (e.g., conization, LEEP, laser)
  • Any other condition deemed unsuitable for participation by the investigator
  • Pregnant or breastfeeding women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 25 and 65 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL/CIN2, aiming to demonstrate non-inferiority in clinical efficacy.

The 2 groups in the trial

  • ALA-PDT GroupTreatment being tested

    ALA-PDT treatment for cervical lesions 6 to 9 times

    Treatment: ALA-PDT

  • LEEP GroupExisting treatment, for comparison

    LEEP surgery for cervical lesions

    Treatment: LEEP surgery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07306260, who can take part
Record updated
14 October 2026